RedChip Initiates Research Coverage on Pressure BioSciences

Share Article

RedChip Research has initiated coverage of Pressure BioSciences (OTCQB: PBIO), a company that develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6 billion life sciences sample preparation market.

PBIO's patented Pressure Cycling Technology ("PCT") platform uses alternate cycles of hydrostatic pressure between ambient and ultra-high levels (up to 90,000 psi) to safely and conveniently control the rupture (lysis) of cells and tissues from human, animal, plant and microbial sources. The Company has sold approximately 300 instrument systems worldwide to leading academic, government, biotech and pharma laboratories. Additionally, there have been over 100 journal articles and peer reviewed publications on the advantages of PCT technology. In January 2016, the Company announced a co-marketing deal with SCIEX (global leader in mass spectrometry), and in March 2017 an expansion of the Company's sales and marketing team. These positive changes should begin to show strong sales increases going forward.

PBIO CEO Richard T. Schumacher is a serial entrepreneur who has had substantial success in founding, growing, and operating Biotech and Pharma businesses in the past; as the initial President and Co- founder of Panacos Pharma, he helped to significantly improve the Company from a struggling start-up to a $700 million market cap company in seven years. Relative to sales potential, if PBIO can capture just 25% of the market opportunity in mass spectrometry, we believe it could lead to $75 million in device sales and $36 million in annual recurring revenue. Additional long-term opportunities for PCT also exist.

To learn more about PBIO, please visit http://www.pbioinfo.com

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Victor Roberts
Visit website